Shelly Lu
Director, Karsh Division of Gastroenterology and Hepatology
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (4)
Prostate adenocarcinoma resistance to androgen receptor (AR) signaling inhibitor therapy is associated with elevated glutamine (L-Gln). Glutamine sensors, present in conserved riboswitches (glnA), control nitrogen metabolism in many organisms, such as cyanobacteria. Iterative in silico modifications of glnA found in Synechococcus elongatus and thermodynamic analysis of a 56mer aptamer resulted in high L-Gln specificity and affinity. The optimized aptamer depleted L-Gln from prostate adenocarcinoma cells by both L-Gln sequestration and extracellular glutaminase activation, serving as an allosteric activator. Glutamine depletion reduced FOXM1 transcriptional occupancy on the promoter of FGF8, a known mediator of prostate adenocarcinoma castration resistance. A point mutation in the binding pocket of the 56mer rendered the aptamer ineffective in L-Gln binding and FGF8 regulation. Accordingly, the L-Gln–depleting aptamer, with demonstrated serum stability, limited the proliferation and promoted cell death of castration-resistant prostate adenocarcinoma alone and in combination therapy with AR antagonists, enzalutamide and apalutamide, in subcutaneous and orthotopic mouse models. Further selective tumor targeting was achieved by functionalizing gold nanoparticles with either the optimized L-Gln aptamer or the point-mutant aptamer. Castration sensitivity was restored by the L-Gln–depleting aptamer but not by the point-mutant aptamer. The functionalized nanoparticle demonstrated superior antitumor efficacy in an orthotopic prostate adenocarcinoma model compared with the untargeted aptamer. The antitumor activity of the aptamer helped support L-Gln as an oncometabolite in prostate adenocarcinoma that can be targeted to sensitize tumors to hormone therapy. Significance: Depletion of glutamine, which can mediate hormone therapy resistance in prostate cancer patients, with a cyanobacteria-derived catalytic aptamer blocks FGF8 expression and sensitizes hormone refractive prostate tumors to androgen receptor inhibitors.
Year:
2025
Year:
2025
Prostate adenocarcinoma resistance to androgen receptor (AR) signaling inhibitor therapy is associated with elevated glutamine (L-Gln). Glutamine sensors, present in conserved riboswitches (glnA), control nitrogen metabolism in many organisms, such as cyanobacteria. Iterative in silico modifications of glnA found in Synechococcus elongatus and thermodynamic analysis of a 56mer aptamer resulted in high L-Gln specificity and affinity. The optimized aptamer depleted L-Gln from prostate adenocarcinoma cells by both L-Gln sequestration and extracellular glutaminase activation, serving as an allosteric activator. Glutamine depletion reduced FOXM1 transcriptional occupancy on the promoter of FGF8 , a known mediator of prostate adenocarcinoma castration resistance. A point mutation in the binding pocket of the 56mer rendered the aptamer ineffective in L-Gln binding and FGF8 regulation. Accordingly, the L-Gln–depleting aptamer, with demonstrated serum stability, limited the proliferation and promoted cell death of castration-resistant prostate adenocarcinoma alone and in combination therapy with AR antagonists, enzalutamide and apalutamide, in subcutaneous and orthotopic mouse models. Further selective tumor targeting was achieved by functionalizing gold nanoparticles with either the optimized L-Gln aptamer or the point-mutant aptamer. Castration sensitivity was restored by the L-Gln–depleting aptamer but not by the point-mutant aptamer. The functionalized nanoparticle demonstrated superior antitumor efficacy in an orthotopic prostate adenocarcinoma model compared with the untargeted aptamer. The antitumor activity of the aptamer helped support L-Gln as an oncometabolite in prostate adenocarcinoma that can be targeted to sensitize tumors to hormone therapy. Significance: Depletion of glutamine, which can mediate hormone therapy resistance in prostate cancer patients, with a cyanobacteria-derived catalytic aptamer blocks FGF8 expression and sensitizes hormone refractive prostate tumors to androgen receptor inhibitors.
Year:
2025
Lipidomics has unveiled the intricate human lipidome, emphasizing the extensive diversity within lipid classes in mammalian tissues critical for cellular functions. This diversity poses a challenge in maintaining a delicate balance between adaptability to recurring physiological changes and overall stability. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), linked to factors such as obesity and diabetes, stems from a compromise in the structural and functional stability of the liver within the complexities of lipid metabolism. This compromise inaccurately senses an increase in energy status, such as during fasting-feeding cycles or an upsurge in lipogenesis. Serum lipidomic studies have delineated three distinct metabolic phenotypes, or “metabotypes” in MASLD. MASLD-A is characterized by lower very low-density lipoprotein (VLDL) secretion and triglyceride (TG) levels, associated with a reduced risk of cardiovascular disease (CVD). In contrast, MASLD-C exhibits increased VLDL secretion and TG levels, correlating with elevated CVD risk. An intermediate subtype, with a blend of features, is designated as the MASLD-B metabotype. In this perspective, we examine into recent findings that show the multifaceted regulation of VLDL secretion by S-adenosylmethionine, the primary cellular methyl donor. Furthermore, we explore the differential CVD and hepatic cancer risk across MASLD metabotypes and discuss the context and potential paths forward to gear the findings from genetic studies towards a better understanding of the observed heterogeneity in MASLD.
Year:
2024
Collaborators (4)
Ekihiro Seki
Professor
Cedars-Sinai Medical Center
Maria Lauda Tomasi
Cedars-Sinai Medical Center
Gabrielle Gonzales Gabrielle Gonzales
The Lundquist Institute
David Underhill
Professor
Cedars-Sinai Medical Center
Make your next move.
Prepare your application
Review drafts before you send them.